SARS-CoV-2 is not unique in its ability to cause post-acute sequelae; certain acute
infections have long been associated with an unexplained chronic disability in a minority of …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Background There are a growing number of case reports of various autoimmune diseases
occurring after COVID-19, yet there is no large-scale population-based evidence to support …

Abstract Coronavirus disease 2019 (COVID-19) has been categorized as evolving in
overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the
coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including …

Multisystem inflammatory syndrome in children (MIS-C) is a febrile pediatric inflammatory
disease that may develop weeks after initial SARS-CoV-2 infection or exposure. MIS-C …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

Here, we report an update of the VDJdb database with a substantial increase in the number
of T-cell receptor (TCR) sequences and their cognate antigens. The update further provides …

Immune tolerance deletes or suppresses autoreactive lymphocytes and is established at
multiple levels during the development, activation and effector phases of T and B cells …

Microfold (M) cells are located in the epithelium covering mucosa-associated lymphoid
tissues, such as the Peyer's patches (PPs) of the small intestine. M cells actively transport …